Legal & General Group PLC Coherus Bio Sciences, Inc. Transaction History

Legal & General Group PLC

  • $431 Billion
  • Q3 2025

A detailed history of Legal & General Group PLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 9,272 shares of CHRS stock, worth $11,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,272
Previous 11,625 20.24%
Holding current value
$11,033
Previous $8,000 87.5%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025
SELL
$0.75 - $1.7 $1,764 - $4,000
-2,353 Reduced 20.24%
9,272 $15,000
Q3 2024

Nov 14, 2024
BUY
$0.99 - $1.8 $2,475 - $4,500
2,500 Added 27.4%
11,625 $12,000
Q2 2024

May 29, 2025
SELL
$1.58 - $2.51 $1,611 - $2,560
-1,020 Reduced 10.05%
9,125 $15,000
Q2 2024

Aug 14, 2024
SELL
$1.58 - $2.51 $1,611 - $2,560
-1,020 Reduced 10.05%
9,125 $15,000
Q1 2024

May 29, 2025
SELL
$2.02 - $3.14 $2,989 - $4,647
-1,480 Reduced 12.73%
10,145 $24,000
Q1 2024

May 14, 2024
SELL
$2.02 - $3.14 $148,453 - $230,764
-73,492 Reduced 87.87%
10,145 $24,000
Q4 2023

May 29, 2025
BUY
$1.59 - $3.85 $114,499 - $277,246
72,012 Added 619.46%
83,637 $278,000
Q3 2023

Nov 14, 2023
SELL
$3.74 - $5.45 $410,562 - $598,279
-109,776 Reduced 56.76%
83,637 $312,000
Q2 2023

Aug 14, 2023
BUY
$3.79 - $8.3 $138,247 - $302,759
36,477 Added 23.24%
193,413 $825,000
Q1 2023

May 15, 2023
SELL
$5.89 - $10.52 $6,449 - $11,519
-1,095 Reduced 0.69%
156,936 $1.07 Million
Q4 2022

Feb 14, 2023
BUY
$5.69 - $10.07 $16,950 - $29,998
2,979 Added 1.92%
158,031 $1.25 Million
Q3 2022

Nov 14, 2022
BUY
$7.17 - $13.87 $17,516 - $33,884
2,443 Added 1.6%
155,052 $1.49 Million
Q2 2022

Aug 22, 2022
SELL
$5.86 - $13.23 $2,795 - $6,310
-477 Reduced 0.31%
152,609 $1.11 Million
Q1 2022

May 16, 2022
SELL
$10.92 - $16.41 $18,585 - $27,929
-1,702 Reduced 1.1%
153,086 $1.98 Million
Q4 2021

Feb 14, 2022
BUY
$15.81 - $18.99 $77,848 - $93,506
4,924 Added 3.29%
154,788 $2.47 Million
Q3 2021

Nov 15, 2021
BUY
$12.68 - $17.79 $88,024 - $123,498
6,942 Added 4.86%
149,864 $2.41 Million
Q2 2021

Aug 12, 2021
SELL
$12.95 - $15.41 $510,411 - $607,369
-39,414 Reduced 21.62%
142,922 $1.98 Million
Q1 2021

May 17, 2021
BUY
$14.42 - $21.39 $88,481 - $131,249
6,136 Added 3.48%
182,336 $2.66 Million
Q4 2020

Feb 12, 2021
BUY
$16.56 - $18.94 $13,181 - $15,076
796 Added 0.45%
176,200 $3.06 Million
Q3 2020

Nov 13, 2020
BUY
$17.41 - $19.89 $88,999 - $101,677
5,112 Added 3.0%
175,404 $3.22 Million
Q2 2020

Aug 14, 2020
BUY
$14.43 - $19.16 $2.25 Million - $2.99 Million
156,059 Added 1096.46%
170,292 $3.04 Million
Q1 2020

May 14, 2020
SELL
$11.67 - $22.53 $9,697 - $18,722
-831 Reduced 5.52%
14,233 $231,000
Q4 2019

Feb 13, 2020
BUY
$16.33 - $21.37 $16,689 - $21,840
1,022 Added 7.28%
15,064 $271,000
Q3 2019

Nov 13, 2019
BUY
$16.3 - $23.37 $39,120 - $56,088
2,400 Added 20.62%
14,042 $284,000
Q2 2019

Aug 14, 2019
BUY
$13.1 - $22.1 $26,855 - $45,305
2,050 Added 21.37%
11,642 $257,000
Q1 2019

May 15, 2019
BUY
$8.38 - $15.5 $4,164 - $7,703
497 Added 5.46%
9,592 $131,000
Q4 2018

Feb 15, 2019
BUY
$8.65 - $16.28 $8,632 - $16,247
998 Added 12.33%
9,095 $82,000
Q3 2018

Nov 20, 2018
BUY
$14.45 - $20.25 $11,603 - $16,260
803 Added 11.01%
8,097 $133,000
Q2 2018

Aug 10, 2018
BUY
$10.25 - $17.45 $1,701 - $2,896
166 Added 2.33%
7,294 $102,000
Q1 2018

May 17, 2018
SELL
$9.1 - $13.7 $29,656 - $44,648
-3,259 Reduced 31.38%
7,128 $78,000
Q4 2017

Feb 13, 2018
BUY
$8.35 - $14.4 $86,731 - $149,572
10,387
10,387 $92,000

Others Institutions Holding CHRS

# of Institutions
125
Shares Held
54.7M
Call Options Held
291K
Put Options Held
120K
View Full List

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $92.5M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email